ABCG2 and cancer: Compounds (40, 57, 94) were shown to sensitize K562/breast cancer resistance protein (BCRP) cells to the metabolically active product camptothecin, SN-38, by inhibiting the function of BCRP cells, thereby demonstrating that they could alter multidrug resistance in cancer treatment (Morita et al., 2005).